AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30753272 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib 30 mg daily and olaparib capsules 200 mg twice daily
Number of subjects: 90
Study 30753272 — intervention group
Group type: COMPARATOR
Intervention: olaparib capsules 400 mg twice daily
Number of subjects: 90
Study 30753272 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib/olaparib combination in gBRCA wild-type/unknown patients
Number of subjects: 90
Study 30753272 — intervention group
Group type: COMPARATOR
Intervention: olaparib alone in gBRCA wild-type/unknown patients
Number of subjects: 90
Study 30753272 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib/olaparib combination in overall study population
Number of subjects: 90
Study 30753272 — intervention group
Group type: COMPARATOR
Intervention: olaparib alone in overall study population
Number of subjects: 90
Study 30753272 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib/olaparib combination in gBRCAm patients
Number of subjects: 90
Study 29140808 — intervention group
Group type: EXPERIMENTAL
Intervention: AGE with supplements (AGE+S)
Number of subjects: 60
Study 26947961 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (Protexa)
Number of subjects: 50
Study 26947961 — intervention group
Group type: COMPARATOR
Intervention: Titanized mesh (TiLOOP Bra)
Number of subjects: 50
Study 24469906 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg lumiracoxib
Number of subjects: 18
Study 24469906 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg etoricoxib
Number of subjects: 18
Study 21543209 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (diet I)
Number of subjects: 249
Study 21543209 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (diet II)
Number of subjects: 249
Study 21543209 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (wild-type group)
Number of subjects: 249
Study 21543209 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (mutant-type group)
Number of subjects: 249
Study 20120791 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplements
Number of subjects: 2378
Study 20120791 — intervention group
Group type: COMPARATOR
Intervention: Iron-folic acid supplements
Number of subjects: 2378
Study 17255882 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (Group H, 45 g/d), HES 130/0.4 (Group M, 30 g/d), HES 130/0.4 (Group L, 15 g/d)
Number of subjects: 210
Study 17255882 — intervention group
Group type: COMPARATOR
Intervention: Glucose 5% (Group G)
Number of subjects: 210
Study 17255882 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 130/0.4 (all subgroups)
Number of subjects: 210
Study 16130206 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 740
Study 16130206 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 740
Study 12141616 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking (25 or more cigarettes daily)
Number of subjects: 4470
Study 12141616 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smoking
Number of subjects: 4470
Study 12141616 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 4470
Study 12141616 — intervention group
Group type: EXPERIMENTAL
Intervention: History of angina
Number of subjects: 4470
Study 12141616 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 4470
Study 12141616 — intervention group
Group type: COMPARATOR
Intervention: Overall prevalence of PAD
Number of subjects: 4470
Study 10368941 — intervention group
Group type: EXPERIMENTAL
Intervention: Older participants with less internal LOC
Number of subjects: 0
Study 10368941 — intervention group
Group type: COMPARATOR
Intervention: Younger participants
Number of subjects: 0
Study 8697161 — intervention group
Group type: EXPERIMENTAL
Intervention: T wave inversion myocardial infarction
Number of subjects: 93
Study 8697161 — intervention group
Group type: COMPARATOR
Intervention: ST segment depression myocardial infarction
Number of subjects: 93
Study 2000790 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 199
Study 2000790 — intervention group
Group type: COMPARATOR
Intervention: Conventional antiarrhythmic agents guided by electrophysiologic testing or Holter recording
Number of subjects: 199
Study 6829492 — intervention group
Group type: EXPERIMENTAL
Intervention: semustine (MeCCNU) plus vincristine (VCR)
Number of subjects: 232
Study 6829492 — intervention group
Group type: EXPERIMENTAL
Intervention: semustine (MeCCNU) plus dacarbazine (DTIC)
Number of subjects: 232
Study 6829492 — intervention group
Group type: EXPERIMENTAL
Intervention: semustine (MeCCNU) plus DTIC plus vincristine (VCR)
Number of subjects: 232
Study 6829492 — intervention group
Group type: EXPERIMENTAL
Intervention: semustine (MeCCNU) plus beta‐2'‐deoxythioguanosine (beta‐TGdR)
Number of subjects: 232
Study 31653221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and subsequent long-term oral tranexamic acid (TXA) at 20-mg/kg 10 min before surgery and 3 h postoperatively, then oral 1 g TXA from POD 1 to POD 14
Number of subjects: 118
Study 31653221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and subsequent long-term oral tranexamic acid (TXA)
Number of subjects: 118
Study 31653221 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral 1 g from POD 1 to POD 14)
Number of subjects: 118
Study 29374249 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly vitamin D3 50,000 IU orally monthly plus three placebo tablets 3-monthly
Number of subjects: 28
Study 29374249 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly vitamin D3 150,000 IU (3 × 50,000 IU tablets) 3-monthly and placebo orally monthly
Number of subjects: 28
Study 29374249 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo monthly and three placebo tablets 3-monthly)
Number of subjects: 28
Study 27038788 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intensive strategy (TIS)
Number of subjects: 44
Study 27038788 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (CS)
Number of subjects: 44
Study 25712255 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 (500 µg), Folic Acid (400 µg), and Vitamin D (600 IU) supplementation for 2 years
Number of subjects: 1111
Study 25712255 — intervention group
Group type: COMPARATOR
Intervention: Placebo with Vitamin D (600 IU) for 2 years
Number of subjects: 1111
Study 25712255 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 and Folic Acid supplementation
Number of subjects: 1111
Study 23435026 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical hypnosis
Number of subjects: 187
Study 23435026 — intervention group
Group type: COMPARATOR
Intervention: Structured-attention control
Number of subjects: 187
Study 20880169 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of oral revaprazan daily for 7 days
Number of subjects: 30
Study 20880169 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of oral revaprazan daily for 7 days
Number of subjects: 30
Study 20880169 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of oral revaprazan daily for 7 days
Number of subjects: 30
Study 18242267 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematocrit 25%
Number of subjects: 124
Study 18242267 — intervention group
Group type: COMPARATOR
Intervention: Hematocrit 35%
Number of subjects: 124
Study 16633920 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT Leu84Phe polymorphism
Number of subjects: 2500
Study 16633920 — intervention group
Group type: EXPERIMENTAL
Intervention: MGMT Ile143Val polymorphism
Number of subjects: 2500
Study 16633920 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-environment interactions with Leu84Phe polymorphism
Number of subjects: 2500
Study 16633920 — intervention group
Group type: COMPARATOR
Intervention: MGMT Leu84Phe and Ile143Val polymorphisms
Number of subjects: 2500
Study 14564327 — intervention group
Group type: EXPERIMENTAL
Intervention: AlereNet system (Alere Medical, Reno, Nev)
Number of subjects: 280
Study 14564327 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 280
Study 10840005 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin (eptifibatide) Therapy
Number of subjects: 9461
Study 9108980 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann tonometry without fluorescein and anesthesia with contact lenses
Number of subjects: 20
Study 9108980 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann tonometry without fluorescein with -1.0 D soft contact lenses
Number of subjects: 20
Study 9108980 — intervention group
Group type: EXPERIMENTAL
Intervention: Tono‐Pen tonometry
Number of subjects: 20
Study 9108980 — intervention group
Group type: COMPARATOR
Intervention: Conventional Goldmann tonometry with fluorescein without contact lenses
Number of subjects: 20
Study 1609767 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra (36 g fat replacement)
Number of subjects: 24
Study 1609767 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra (20 g fat replacement)
Number of subjects: 24
Study 1609767 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra (0 g fat replacement)
Number of subjects: 24
Study 1609767 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 2868040 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (500 mg)
Number of subjects: 55
Study 2868040 — intervention group
Group type: COMPARATOR
Intervention: No vancomycin
Number of subjects: 55
Study 31926554 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - TFLM protected by an autogenous tissue 'pad' from the anterior capsule of the joint.
Number of subjects: 56
Study 31926554 — intervention group
Group type: COMPARATOR
Intervention: Group B - No protection of the TFLM, with surgeons attempting to avoid injury.
Number of subjects: 56
Study 30017831 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedaplatin (80 mg/m2) plus Docetaxel (75 mg/m2)
Number of subjects: 280
Study 30017831 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (75 mg/m2) plus Docetaxel (75 mg/m2)
Number of subjects: 280
Study 27617409 — intervention group
Group type: EXPERIMENTAL
Intervention: DBBMC + NBCM
Number of subjects: 40
Study 27617409 — intervention group
Group type: COMPARATOR
Intervention: DFDBA + RECXC
Number of subjects: 40
Study 27617409 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 40
Study 24920550 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMB
Number of subjects: 10
Study 24920550 — intervention group
Group type: EXPERIMENTAL
Intervention: HBR
Number of subjects: 10
Study 24920550 — intervention group
Group type: COMPARATOR
Intervention: NBR
Number of subjects: 10
Study 21629990 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (10 mg/kg q2w) plus Cetuximab (400/250 mg/m(2) initial/weekly) with Gemcitabine (1000 mg/m(2) weekly × 3 of 4 weeks)
Number of subjects: 61
Study 21629990 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (10 mg/kg q2w) plus Cetuximab (400/250 mg/m(2) initial/weekly) without Gemcitabine
Number of subjects: 61
Study 20860915 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg Mouth dissolving tablet, Ranbaxy (test product)
Number of subjects: 24
Study 20860915 — intervention group
Group type: COMPARATOR
Intervention: Risperdal 1 mg Quicklet (reference product)
Number of subjects: 24
Study 19009508 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone (PS) membrane
Number of subjects: 15
Study 19009508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose triacetate (CTA) membrane
Number of subjects: 15
Study 19009508 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) membrane
Number of subjects: 15
Study 15735910 — intervention group
Group type: EXPERIMENTAL
Intervention: Hu-D peptides (19 selected peptides)
Number of subjects: 20
Study 12911564 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate-based modeled volume of urea (Vm)
Number of subjects: 0
Study 12911564 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based modeled volume of urea (Vm)
Number of subjects: 0
Study 12911564 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric estimates of total body water (TBW) using Watson, Hume-Weyers, and Chertow equations
Number of subjects: 0
Study 12911564 — intervention group
Group type: EXPERIMENTAL
Intervention: Watson equation for TBW
Number of subjects: 0
Study 12911564 — intervention group
Group type: EXPERIMENTAL
Intervention: Chertow equation for TBW
Number of subjects: 0
Study 12911564 — intervention group
Group type: EXPERIMENTAL
Intervention: Hume-Weyers formula for TBW
Number of subjects: 0
Study 12911564 — intervention group
Group type: EXPERIMENTAL
Intervention: Watson estimate for TBW
Number of subjects: 0
Study 10924844 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day, n=15)
Number of subjects: 30
Study 10924844 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (40 mg/day, n=15)
Number of subjects: 30
Study 10924844 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiestrogen regimen (Tamoxifen and Toremifene)
Number of subjects: 30
Study 8677805 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial visual analysis
Number of subjects: 0
Study 8677805 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed visual analysis
Number of subjects: 0
Study 8199723 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5-20 mg daily
Number of subjects: 28
Study 8199723 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50-200 mg daily
Number of subjects: 28
Study 8199723 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Felodipine and Metoprolol
Number of subjects: 28
Study 8199723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3328329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil (20 mg base weekly)
Number of subjects: 0
Study 3328329 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (200 mg base weekly)
Number of subjects: 0
Study 3328329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil + Chloroquine (20 mg base + 200 mg base weekly)
Number of subjects: 0
Study 3328329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil (20 mg base weekly) in children weighing 15-24 kg
Number of subjects: 0
Study 3328329 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (200 mg base weekly) in children weighing 15-24 kg
Number of subjects: 0
Study 3328329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil + Chloroquine in children weighing 25-39 kg
Number of subjects: 0
Study 3328329 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil + Chloroquine
Number of subjects: 0
Study 3328329 — intervention group
Group type: EXPERIMENTAL
Intervention: All treated groups
Number of subjects: 0
Study 3328329 — intervention group
Group type: COMPARATOR
Intervention: Non-protected children
Number of subjects: 0
Study 31699660 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20-mg equivalent dose, bodyweight-adjusted)
Number of subjects: 500
Study 31699660 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulants (heparin or switched to vitamin K antagonist)
Number of subjects: 500
Study 31699660 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 500
Study 31699660 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulants
Number of subjects: 500
Study 29620137 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit®‐based balance rehabilitation
Number of subjects: 23
Study 29620137 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (Control)
Number of subjects: 23
Study 27155612 — intervention group
Group type: EXPERIMENTAL
Intervention: NO2 concentration 0.5 ppm
Number of subjects: 25
Study 27155612 — intervention group
Group type: COMPARATOR
Intervention: NO2 concentration 0.1 ppm
Number of subjects: 25
Study 27155612 — intervention group
Group type: EXPERIMENTAL
Intervention: NO2 concentration 1.5 ppm
Number of subjects: 25
Study 27155612 — intervention group
Group type: COMPARATOR
Intervention: NO2 concentration 0 ppm
Number of subjects: 25
Study 26342481 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (300 mg twice daily for 6 months)
Number of subjects: 75
Study 26342481 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 75
Study 24171888 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 96
Study 24171888 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 96
Study 20721612 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination intervention
Number of subjects: 100
Study 20721612 — intervention group
Group type: COMPARATOR
Intervention: Care coordination intervention (after wait list control group received it)
Number of subjects: 100
Study 20721612 — intervention group
Group type: EXPERIMENTAL
Intervention: Care coordination intervention (within subject analysis)
Number of subjects: 100
Study 19577992 — intervention group
Group type: COMPARATOR
Intervention: Radial access
Number of subjects: 13819
Study 19577992 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin monotherapy
Number of subjects: 13819
Study 17998187 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive interactive neurostimulation device
Number of subjects: 60
Study 17998187 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 60
Study 15531680 — intervention group
Group type: EXPERIMENTAL
Intervention: MM supplements (vitamins A, B complex, C, D, E, and K and iron, zinc, and magnesium; 6 d/wk for 12 wk)
Number of subjects: 158
Study 15531680 — intervention group
Group type: COMPARATOR
Intervention: Iron alone (60 mg; 6 d/wk for 12 wk)
Number of subjects: 158
Study 11172190 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (200 U)
Number of subjects: 145
Study 11172190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 11172190 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (100 U) after initial placebo treatment
Number of subjects: 145
Study 11172190 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A (200 U) and Placebo (100 U) after 24 weeks
Number of subjects: 145
Study 11074107 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy (IPT‐G)
Number of subjects: 0
Study 11074107 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 7633178 — intervention group
Group type: EXPERIMENTAL
Intervention: NTG i.v. (n = 29)
Number of subjects: 95
Study 2619149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac solution 0.5% eye drops
Number of subjects: 0
Study 2619149 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone sodium phosphate solution 0.1% eye drops
Number of subjects: 0
Study 23706 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dimethpyrindene (0.1 mg/kg b.w.) and cimetidine (10 mg/kg b.w.)
Number of subjects: 50
Study 23706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 50
Study 30601234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohesive silicone bandage
Number of subjects: 60
Study 30601234 — intervention group
Group type: COMPARATOR
Intervention: Silicone gel sheet
Number of subjects: 60
Study 29798375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone (10 mg/ml)
Number of subjects: 108
Study 29798375 — intervention group
Group type: COMPARATOR
Intervention: Post-auricular subperiosteal injection of methylprednisolone (40 mg/ml)
Number of subjects: 108
Study 25773936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous contrast enhanced-CT (CE-CT)
Number of subjects: 511
Study 23018991 — intervention group
Group type: EXPERIMENTAL
Intervention: Active left atrial (LA) pacing
Number of subjects: 6
Study 23018991 — intervention group
Group type: COMPARATOR
Intervention: Inactive left atrial (LA) pacing
Number of subjects: 6
Study 21079055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180‐mg load, 90 mg BID)
Number of subjects: 174
Study 21079055 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600‐mg load, 75 mg/d)
Number of subjects: 174
Study 21079055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 174
Study 18198059 — intervention group
Group type: EXPERIMENTAL
Intervention: LED high‐intensity units (Elipar Freelight2, Bluephase)
Number of subjects: 70
Study 18198059 — intervention group
Group type: COMPARATOR
Intervention: Halogen light‐curing unit (Prismetics Lite 2)
Number of subjects: 70
Study 16809803 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride
Number of subjects: 40
Study 16809803 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro system
Number of subjects: 40
Study 14555500 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant (FVT) 250 mg i.m. monthly
Number of subjects: 851
Study 14555500 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (ANZ) 1 mg p.o. daily
Number of subjects: 851
Study 10656303 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas permeable (RGP) contact lenses
Number of subjects: 29
Study 10656303 — intervention group
Group type: COMPARATOR
Intervention: Best corrected spectacle visual acuity
Number of subjects: 29
Study 1978871 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular inhaled bronchodilator treatment (fenoterol)
Number of subjects: 89
Study 1978871 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 89
Study 6772381 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocainide (17.7 +/- 4.9 mg/kg/day)
Number of subjects: 18
Study 6772381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30320644 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 100
Study 30320644 — intervention group
Group type: COMPARATOR
Intervention: self-pressurized air-Q
Number of subjects: 100
Study 30320644 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 31673207 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad Shot regimen (14 Gy in 4 fractions given twice a day at least 6 h apart for 2 consecutive days, repeated at 4 weekly intervals for a further two courses if no tumor progression)
Number of subjects: 50